The latest price target for PDS Biotechnology (NASDAQ:PDSB) was reported by HC Wainwright & Co. on March 27, 2025. The analyst firm set a price target for $13.00 expecting PDSB to rise to within 12 months (a possible 870.15% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for PDS Biotechnology (NASDAQ:PDSB) was provided by HC Wainwright & Co., and PDS Biotechnology maintained their buy rating.

There is no last upgrade for PDS Biotechnology

There is no last downgrade for PDS Biotechnology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PDS Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PDS Biotechnology was filed on March 27, 2025 so you should expect the next rating to be made available sometime around March 27, 2026.

While ratings are subjective and will change, the latest PDS Biotechnology (PDSB) rating was a maintained with a price target of $21.00 to $13.00. The current price PDS Biotechnology (PDSB) is trading at is $1.34, which is out of the analyst’s predicted range.